Prudential Financial Portfolio holdings
AUM
$77.4B
1-Year Return
21.48%
This Quarter Return
+12.74%
1 Year Return
+21.48%
3 Year Return
+96.22%
5 Year Return
+175.48%
10 Year Return
+394.71%
AUM
$66.2B
AUM Growth
+$2.36B
(+3.7%)
Cap. Flow
-$4.5B
Cap. Flow
% of AUM
-6.8%
Top 10 Holdings %
Top 10 Hldgs %
26.27%
Holding
2,763
New
170
Increased
1,022
Reduced
1,381
Closed
119
Top Buys
| 1 |
iShares Core S&P 500 ETF
IVV
|
$1.25B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
$294M |
| 3 |
S&P Global
SPGI
|
$128M |
| 4 |
iShares Russell 1000 Growth ETF
IWF
|
$123M |
| 5 |
iShares Russell 1000 Value ETF
IWD
|
$122M |
Top Sells
| 1 |
Microsoft
MSFT
|
$441M |
| 2 |
Apple
AAPL
|
$425M |
| 3 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
$341M |
| 4 |
Eli Lilly
LLY
|
$255M |
| 5 |
Mastercard
MA
|
$221M |
Sector Composition
| 1 | Technology | 23.69% |
| 2 | Financials | 10.78% |
| 3 | Healthcare | 10.73% |
| 4 | Consumer Discretionary | 9.54% |
| 5 | Industrials | 7.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Planet Labs
PL
$1.98B
| $26.5K | ﹤0.01% |
10,715
| – | – |
|
|
NGM
2602
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $25.6K | ﹤0.01% |
+29,785
| New | +$25.6K |
|
2603
CytomX Therapeutics
CTMX
$376M
| $25.3K | ﹤0.01% |
16,300
| – | – |
|
2604
ChargePoint
CHPT
$239M
| $25K | ﹤0.01% |
+534
| New | +$25K |
|
2605
Inuvo
INUV
$49M
| $24.1K | ﹤0.01% |
+5,660
| New | +$24.1K |
|
2606
SCYNEXIS
SCYX
$37.3M
| $23.6K | ﹤0.01% |
10,600
| – | – |
|
2607
Cartesian Therapeutics
RNAC
$277M
| $23.4K | ﹤0.01% |
1,130
| – | – |
|
2608
Bionano Genomics
BNGO
$18.7M
| $23.2K | ﹤0.01% |
+205
| New | +$23.2K |
|
|
SHCR
2609
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
| $22K | ﹤0.01% |
20,395
+1,730
| +9% | +$1.87K |
|
|
FSR
2610
DELISTED
Fisker Inc.
FSR
| $21.9K | ﹤0.01% |
12,517
| – | – |
|
2611
Karyopharm Therapeutics
KPTI
$57.2M
| $21.5K | ﹤0.01% |
1,654
+360
| +28% | +$4.67K |
|
|
ATYR
2612
aTyr Pharma
ATYR
$550M
| $21.4K | ﹤0.01% |
+15,200
| New | +$21.4K |
|
2613
FibroGen
FGEN
$48.9M
| $21.1K | ﹤0.01% |
952
| – | – |
|
2614
Exagen
XGN
$213M
| $21.1K | ﹤0.01% |
10,600
| – | – |
|
|
AGEN
2615
Agenus
AGEN
$138M
| $20.2K | ﹤0.01% |
1,222
+125
| +11% | +$2.07K |
|
|
PVLA
2616
Palvella Therapeutics, Inc. Common Stock
PVLA
$616M
| $20.1K | ﹤0.01% |
1,378
| – | – |
|
2617
Gevo
GEVO
$404M
| $19.8K | ﹤0.01% |
17,090
-322,630
| -95% | -$374K |
|
2618
Microvast
MVST
$829M
| $19.2K | ﹤0.01% |
+13,715
| New | +$19.2K |
|
|
IAUX
2619
i-80 Gold Corp
IAUX
$694M
| $18.5K | ﹤0.01% |
+10,520
| New | +$18.5K |
|
2620
Kezar Life Sciences
KZR
$29.8M
| $17.8K | ﹤0.01% |
1,898
-1,755
| -48% | -$16.5K |
|
|
ME
2621
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $16.7K | ﹤0.01% |
915
+173
| +23% | +$3.16K |
|
2622
LiveOne
LVO
$51.2M
| $16.7K | ﹤0.01% |
12,000
-27,200
| -69% | -$37.8K |
|
2623
Nektar Therapeutics
NKTR
$764M
| $15.9K | ﹤0.01% |
1,880
+507
| +37% | +$4.3K |
|
|
BLUE
2624
DELISTED
bluebird bio
BLUE
| $15.9K | ﹤0.01% |
+575
| New | +$15.9K |
|
2625
Vroom, Inc. Common Stock
VRM
$140M
| $15.8K | ﹤0.01% |
327
| – | – |
|